載入...
Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor
BACKGROUND: Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but have received little attention. The drugs, pembrolizumab and nivolumab are recently approved inhibitors of the PD-1 receptor that have overlapping AE profiles...
Na minha lista:
| 發表在: | Eur J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998047/ https://ncbi.nlm.nih.gov/pubmed/27043866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2016.02.010 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|